VERA · Vera Therapeutics, Inc.
$28.30
+1.11% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-6.7
Dividend yield
0.0%
Beta
1.05
Avg volume
2M
Employees
0K
Daily Change %
1.11%
5 Days Change
-2.58%
10 Days Change
1.51%
30 Days Change
-13.03%
60 Days Change
-17.23%
Month to Day Change
-8.68%
Year to Day Change
-44.12%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VERA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
JP Morgan
Overweight$83.00
+193.3% vs priceBank of America
Buy$70.00
+147.3% vs priceGoldman Sachs
Buy$95.00
+235.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Leerink Partners | Initiates | Market Perform | $0.00 → $34.00 |
| 2026-09-08 | JP Morgan | Maintains | Overweight | $76.00 → $83.00 |
| 2026-08-17 | Wedbush | Reiterates | Neutral | $34.00 |
| 2026-08-12 | HC Wainwright & Co. | Maintains | Buy | $125 → $90.00 |
| 2026-08-11 | Wedbush | Maintains | Neutral | $43.00 → $34.00 |
| 2026-07-08 | TD Cowen | Maintains | Buy | $73.00 → $78.00 |
| 2026-07-08 | Guggenheim | Maintains | Buy | $56.00 → $76.00 |
| 2026-07-08 | Wedbush | Maintains | Neutral | $35.00 → $43.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 11.8% below the 50-day MA ($32.10).
- bearish: Price vs 200-day MA: Trading 24.1% below the 200-day MA ($37.31).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.12) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($24.10) and high ($55.67).
VERA Price Chart
Loading chart for VERA…
Fundamentals
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.